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Abstract 
Purpose:  To identify patient-reported outcome measures (PROMs) specifically developed 
and used to assess the impact of ophthalmic disorders in children and to systematically assess 
their quality as a basis for recommendations about their use in clinical and research settings.  
Methods: A systematic review of the literature was performed in MEDLINE, EMBASE, 
PsychINFO, CINAHL and AMED, supplemented by a grey literature search. Papers reporting 
development and validation of questionnaire instruments for assessing patient-reported outcomes 
of an ophthalmic disorder in patients aged 2-18 years were included. Quality was assessed by 
examining the purpose and psychometric properties of the instruments. Strengths and limitations 
were summarised with recommendations regarding use.   
Results: Search identified 17 instruments. Of these, 11 were condition specific and 6 were 
intended for a broader population of children and young people with visual impairment 
regardless of the ophthalmic condition. Three were developed for use in a specific trial and two 
are still in development.  
Conclusions: Paediatric ophthalmology PROM development and application is a developing 
field and new instruments are needed. There is scope for improvement in this area through a) 
clarity of definitions of the underlying constructs intended to be measured at the onset of 
development of new instruments, b) application of child-centred approaches and c) adherence to 
extant guidance and best practice in questionnaire instrument development. 
  
Introduction 
Increasing international emphasis on patient-led assessment of the impact of illness and 
healthcare1-3 has resulted in a proliferation of questionnaires intended to measure the impact of 
illness or disability and treatment from the patient’s perspective (i.e. patient-reported outcome 
measures – PROMs)4.  PROMs include outcomes such as ‘health-related quality of life 
(HRQoL)’, ‘activities of daily living ’or‘ health status’, for example in trials of clinical, educational 
and social interventions5.  
A surge in vision or eye specific PROMs for adults6-13 contrasts with a hitherto dearth of 
conceptually grounded, psychometrically robust, self-report questionnaires (typically referred to 
as instruments in the literature, as they represent measurement tools) suitable for use with 
children and young people. This paucity reflects the present lack of a clear and established 
conceptual framework defining the underlying vision/eye related constructs intended to be 
measured, combined with the challenges of child-centred methodology necessary to drive 
development of such measures.14 A particular problem in both the adult and paediatric literature 
is the frequent (albeit inadvertent) merging of concepts such as vision–related QoL (VQoL), 
visual function and functional vision to describe ‘the impact of visual disability’. This is further 
complicated by the lack of a universally adopted definition of QoL15. Superimposed on this are 
the challenges inherent in studying populations of children with visual impairment (VI) affected 
by disorders which are individually uncommon, rendering development of an appropriate PROM 
methodologically labour-intensive and time-consuming 16. Thus, to date, generic health-related, 
rather than vision or eye specific, PROMs have been used in paediatric ophthalmology17-24. These 
can distinguish children with visual disorders from fully sighted or unaffected children, but they 
have limited value in discriminating between children with the same ophthalmic condition but of 
varying severity or in detecting clinically significant changes over time25. 
Sometimes, as an alternative to using generic paediatric PROMs, vision/eye-specific 
measures for adults have been used in paediatric population26-32. This approach is recognised as 
problematic, because these instruments are not developmentally sensitive and their content and 
formats do not reflect what children understand or value14, 33, 34. For example, they contain items 
that are irrelevant to children (e.g. driving, financial outcomes)10, 12 or use language and response 
categories that are not age-appropriate9, 11. Additionally, disease-specific adult PROMs12, 31 are not 
applicable across a population of children with different ophthalmic disorders. 
Thus, there is a need for child-appropriate vision and eye specific outcome measures that 
can be self-reported, can differentiate between children or young people with specific eye/vision 
conditions and are sensitive to changes over time as a result of natural history and/or treatments. As 
part of our on-going programme of research to develop such VQoL and functional vision 
instruments35 we have undertaken and report here a systematic literature review in which we 
aimed to: a) identify all vision and eye specific PROMs specifically developed and used to assess the 
impact of eye disease and treatment in children, b) assess the quality of the identified instruments 
against conventional criteria, and c) provide recommendations about the use of these PROMs in 
paediatric ophthalmology clinical practice or research.  
 
Methods 
Search Strategy.  MEDLINE, EMBASE, PsychINFO, CINAHL and AMED databases 
were searched systematically without any restrictions on publication date or language, with the 
main concepts being vision and/or eyes, experience, measurement and child (Appendix 1 
provides search and MeSH terms). These citations were exported to EndNote citation manager 
and duplicates removed. A separate citation search was performed on all subsequently included 
original papers and reviews, supplemented by ‘grey’ literature search (i.e. conference abstracts, 
Google search and personal communication). The initial search was carried out in March 2012 
and updated in July 2012 and February 2013.  
Inclusion/Exclusion Criteria and Process. Abstracts were reviewed independently by 3 
researchers (AH, VT, NS) to determine eligibility based on the criteria shown in Table 1. The full 
paper was obtained where there was insufficient information in the abstract to determine 
eligibility. At this stage the papers where abstracts were not in English were excluded as we did 
not have the resources to ensure robust translation to address cross-cultural validity issues. 
 
(Insert Table 1) 
Data Extraction and Quality Assessment. Information was extracted by two researchers 
(AH, NS) and checked by a third (VT), using an agreed data extraction template, focussing on 
instrument description and quality (Appendix 2). Different versions of the same instrument 
reported in different publications were counted as one.  
Using extant criteria for assessing PROMs36, 37 we reviewed the following:  
a) Purpose of the instrument: Whether a clear definition of the construct being measured was 
provided, as well as a clear specification of the instrument aim and the target population. 
b) Content, face and construct validity: Content validity is the extent to which questionnaire items 
reflect all relevant domains of the construct that the instrument aims to measure. To evaluate this 
we examined whether instrument content and item generation and reduction had used firstly,  
appropriate qualitative research techniques (e.g. through interviews, focus groups and 
consultation with patients, supplemented with a literature review and consultations with 
professionals) and secondly, appropriate psychometric approaches (e.g. removing mis-fitting 
items through Rasch or Factor analysis to provide a statistically justified summary score).  Face 
validity refers to the extent to which the content of the instrument appears ‘at face value’ to 
measure what is intended to measure e.g. whether an instrument purportedly measuring QoL 
reflects different domains that QoL, as a multi-dimensional construct, is meant to capture (e.g. 
social, emotional and functional impact). We examined this by looking at the actual content area 
(items and domains) of the instrument. Construct validity refers to the extent to which the 
instrument truly captures the construct under investigation. We examined this by looking at the 
degree to which the instrument i) correlated with another scale intended to measure related or 
unrelated constructs (i.e. convergent and discriminant validity respectively) or ii) discriminated between 
groups expected to differ (i.e. known groups validity – treatment vs. control group).  
c) Reliability: Reliability refers to the consistency of measurement (e.g., over time or 
different conditions). We investigated this by looking at the different types of reliability reported 
e.g. internal consistency (e.g. whether all items within an instrument or instrument domain are related 
to each other, reflecting a common latent construct, using Cronbach’s alpha) and test-retest 
reliability. Other types of reliability were also considered (e.g. inter-rater reliability or person and 
item separation reliability using Rasch analysis).  
After quality assessment (based on the recommendations by Pesudovs et al 200737, 
Appendix 2), for each instrument extracted data were summarised qualitatively in terms of the 
main strengths and limitations of the instruments, supplemented with recommendations 
regarding use.  
Cross-cultural validation criterion was not included in the formal quality assessment as 
the identified instruments were not reviewed for their appropriateness for use in a particular 
cultural setting, but any cross-cultural adaptation attempts have been considered qualitatively with 
respect to instrument recommendations. 
 
Results 
Search Results. Figure 1 illustrates the process of study and instrument identification. 
Sixteen eligible instruments developed between 1999 and 2012 were identified (15 through 
database search and 1 through the grey literature38). The second search update identified through 
grey literature one more article reporting instrument development39 (1). Thus, 17 instruments were 
identified in total.  
                                                          
(1) This recently published instrument was developed as a distinct (rather than revised) second version of an 
existing instrument40 and was therefore subsequently assessed as a stand-alone instrument.  
 
Fifty two articles were excluded following paper review and data extraction (Appendix 3). 
Two articles41, 42 were excluded as the full text was not available in English and we did not have 
resources for a full English translation for the purpose of this review.  
 
(Insert Figure 1) 
 
Instrument description. Of 17 identified instruments, all but one43 were developed and 
validated using the English language (although in different versions). Six are intended for the 
broader population of children and young people with VI, irrespective of the eye condition 
(referred to as ‘all-cause generic VI instruments’) (Table 2a) and 11 for children with specific 
ophthalmic conditions (referred to as ‘eye-disorder specific instruments’) (Table 2b). 
Seven instruments were intended as measures of quality of life (IVI_C44, 45, CVFQ46, 47, 
VQoL_CYP35, IXTQ48-50,  QUICK43, PREP51-54 and CAT-QoL38),  3 of functional vision or visual 
ability (CVAQC55,  LVP-FVQ40, LVP-FVQ II39) , 2 of the impact of treatment for the condition 
(ATI56-64 and EIAQ65),  1 of symptoms (CISS-V1566-75), 1 of both symptoms and quality of life 
(NLDO76-79), 1 of psychosocial impact of the condition (PIQ80) and 1 of well-being (PPQ81, 82). 
The EYE-Q83, 84 is interchangeably referred to as a measure of visual function and quality of life. 
Tables 2a and 2b provide details of the comparison of intended and achieved measured 
constructs and/or domains targeted by these instruments. 
At the time of writing, 2 of the 17 instruments were still in early development stages: a 
QoL questionnaire for children with amblyopia (CAT-QoL38) and a self-report vision-related 
QoL instrument for children and young people with visual impairment (VQoL_CYP35). A further 
3 instruments were developed for specific trials (PREP51-54, EIAQ65 and PPQ81, 82). Thus, these 5 
instruments have not been included in the full quality assessment presented here, but the 
publications cited describe their development and/or application to date.   
 
(Insert Table 2a) 
(Insert Table 2b) 
 
Instrument quality assessment. The 12 instruments assessed for psychometric quality (i.e., 
Appendix 2) are presented in Tables 3a, 3b and 3c, which summarise their purpose, main 
strengths and limitations, as well as conclusions and recommendations regarding their use. Within 
the groupings of ‘all-cause generic VI instruments’ (Table 3a) and ‘eye-disorder specific 
instruments’ (Tables 3b and 3c), the instruments are listed alphabetically, rather than in order of 
psychometric ‘quality value’ (from highest to lowest based on the quality criteria, as presented in 
Appendix 2) because their applicability to the target clinical population or age group of interest, 
as well as an appropriate cross-cultural adaptation, should always be considered first if deciding 
on their use for clinical or research purpose. 
 (Insert Table 3a) 
(Insert Table 3b) 
(Insert Table 3c) 
 
Discussion 
Our review demonstrates that, currently, the field of paediatric ophthalmology PROMs is 
a limited, but dynamically developing area with most reported instruments still subject to further 
development. Only a small number of instruments that we identified (e.g., LVP-FVQ II39, 
IVI_C44 and CVAQC55) are currently in a sufficiently advanced stage in psychometric terms to be 
recommended for use in clinical care. However, even these instruments, like others, would 
benefit from further psychometric improvements, such as testing in larger samples and 
application in trials or other settings to demonstrate their responsiveness. Equally, they may not 
be suitable for all paediatric ophthalmology populations as appropriateness depends on 
applicability to the target clinical population, the cultural context in which instruments are to be 
used and the age group of the subjects.  
Our review highlights the challenges of developing robust child-appropriate PROMs. In 
keeping with practices set out in the adult PROM literature37, available instruments should not be 
employed without first considering carefully their theoretical and psychometric strengths and 
limitations. Nevertheless, for the majority of the instruments identified by our search the focus of 
the papers reporting their development is the measurement aspect, largely neglecting the 
definition of the construct to be measured. Measurement properties of an instrument, including 
different forms of validity and reliability, form the backbone of any tool intended to place the 
severity of an outcome on a reliable and valid scale.  However, we argue that the quality of an 
instrument cannot be judged by these properties alone, which in any case, are strongly influenced 
by the conceptual definition and the theoretical framework underpinning the construct under 
measurement.  
We found that only some instruments provided a definition of the construct measured 
(PIQ80, ATI56, 58, CISS-V1566-68, 73, LVP-FVQ40, LVP-FVQ II 39, CVFQ46, 47 and VQoL_CYP35).  
Despite lacking an explicit definition, the instruments intended to capture functional outcomes, 
such as visual ability (e.g., CVAQC 55),  may not be as susceptible to misconceptions, as they are 
by definition ability and function related, and are therefore likely to correlate closely with 
functional outcomes assessed objectively (e.g. acuity). Failing to define QoL has greater 
implications.  The consensus is that QoL is a subjective, psychological construct encompassing 
multiple domains of life (i.e. emotional, social, independence)99. Translating QoL into 
ophthalmology, therefore, should involve capturing the impact of having a vision or eye disorder 
across all QoL domains. Nevertheless, we found that some investigators appear to assume that 
vision or eye condition related QoL involves measurement of the restriction in eye or vision 
function. Thus, certain measures apparently assessing vision- or eye condition-specific QoL in 
fact comprise scales assessing symptoms or functional ability associated with those conditions 
(e.g. QUICK43 and EYE_Q83, 84).  
This apparent ‘construct conflation’ is not specific to the ophthalmic literature. It has 
been a general side-effect of the World Health Organisation’s broadening of the definition of 
health as ‘a state of complete physical, mental and social wellbeing and not merely the absence of disease or 
infirmity’ (p.100)100 and the subsequent emergence of HRQoL as a patient-reported outcome that 
is distinct from but complementary to objective clinical measures. Thus, researchers have 
identified a ‘disability paradox’ whereby people with severe disabilities and restricted functioning 
are found to report high QoL, which reaffirms the notion that functioning and/or health are only 
some of the facets that affect a person’s perception of the quality of their life101, 102. Thus, 
although vision-related functional and disability outcomes of visual function (e.g. visual acuity) 
and functional vision (e.g. mobility capacity given the available visual functions), or symptoms 
associated with ophthalmic conditions, may be intrinsically related to how a child living with a VI 
or eye disorder feels about their life (i.e., their QoL), these are conceptually distinct aspects of the 
impact of a vision/eye condition and require differential assessment.  
The danger of construct conflation is of potentially misleading findings. For example, if 
an instrument purportedly measuring QoL, but actually measuring function, detects 
‘improvement’ over time as a result of low vision rehabilitation, it would be misleading to suggest 
that the child’s QoL had improved as other QoL domains had not been considered. In other 
words, the effectiveness of this intervention may be incorrectly estimated if it had not been 
assessed whether the child, although more functional, was still unhappy, dependent and socially 
isolated. Similarly, if a measure with items tapping parental perception of the impact of a 
particular condition and associated treatment fails to detect ‘improvement’ following an 
intervention, we cannot assume that the intervention itself is not beneficial for the child if we did 
not ask child-relevant questions of the child in the first place. 
The lack of an explicit construct definition for many instruments made our assessment of 
validity challenging, particularly where there was a mismatch between the instrument intention 
(including the title) and actual content area. Instruments measuring functional vision (construed 
to capture the level of difficulty in performing a vision-specific task, e.g. CVAQC55, LVP-FVQ40, 
LVP-FVQ II39) would be expected to correlate highly with an objective measure of visual 
function (e.g. acuity), both being on a ruler-like scale of ‘difficulty’ related to functioning. 
However, in keeping with the ‘disability paradox’ 101,we argue that QoL measures should not 
necessarily converge with functional outcomes. Instead, it is expected that they should correlate 
with outcomes on other generic HRQoL and psychosocial measures. Despite this, our review 
found that evaluation of construct validity of QoL instruments more usually relies on a 
comparison with a clinical measure such as acuity and contrast sensitivity or solely on observing 
differences between patients with varying severity of a disorder. Similarly, symptom-driven QoL 
measures may diverge from HRQoL and converge with clinical symptom assessment (e.g. 
QUICK43).  
The underlying principle of patient-reported outcomes such as QoL and emotional 
wellbeing is that they are subjectively defined. Therefore, the starting point for every instrument 
should be discussions with patients affected by the condition of interest so that the issues 
relevant to their lives can be captured accurately.  Instruments that do not adopt this method may 
lack content validity and, as argued above, can be misleading. Where item generation through 
discussions with affected individuals (e.g. very young children) is not possible, we recognise the 
role of consulting parents on the impact of the child’s disorder. In this scenario, however, such 
an approach may result in measures that capture (in addition or solely) parental stress and impact 
on the family (e.g. NLDO76-79). One instrument that we identified (IXTQ48, 50) provides an 
example of how the assessment of parental anxieties and QoL can be helpfully separated from 
the child’s with concurrent development of two complementary but distinct, respondent-targeted 
measures.  
Lack of engagement with the target population in the development process has been a 
limitation of a number of identified instruments, but there is encouraging evidence of changing 
trends. Our review identified on-going programmes of research advocating and demonstrating a 
child-centred approach, involving children and young people at all stages of instrument 
development. The CAT-QoL38 is intended as a self-report measure of HRQoL in children 
undergoing treatment for amblyopia aged 5-7 years, and is grounded in individual interviews with 
young children.  Our own research to develop the VQoL_CYP35 uses a theoretical framework of 
‘self-discrepancy between actual experience and expectations’ for capturing the quality of life of 
visually impaired children aged 10-15 years. More recently, DeCarlo et al103 reported the 
methodology for identifying child-related concerns, through focus groups with children and their 
parents, as a basis of a future non-condition-specific vision-targeted HRQoL instrument for use 
with visually impaired children aged 6-12 years. These programmes and others identified in this 
review demonstrate the evolving nature of the paediatric ophthalmology PROM field and 
highlight new approaches to the development of child-appropriate instruments, heralding a 
coming of age for this important scientific area. 
A lack of robust, conceptually grounded instruments renders the routine use of paediatric 
ophthalmology PROMs in clinical practice very difficult at present, despite the high profile of 
this approach in health service planning and policy. The ophthalmic community needs to work 
together to address this challenge. We would encourage clinicians to work with qualitative and 
quantitative scientists and their paediatric patient populations to develop robust, reliable and easy 
to use PROMs. Without this, clinical practice and health policy in paediatric ophthalmology 
cannot be shaped by what matters most to children with visual impairment and/or eye 
conditions.   
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Table 1: Inclusion/exclusion criteria for selection of papers to be considered for review 
Inclusion Exclusion 
Children with visual impairment and/or eye 
disorders, paediatric ophthalmology 
patients/subjects 
Children with non-ophthalmic conditions 
Age 2-18 years  
Questionnaires, scales, instruments, checklists  
 
Patient oriented measures i.e., patient-reported 
and parent proxy reported outcome measures 
(PROMs) 
Objective parameters and tests, clinical 
indicators and those restricted to demographic 
or environmental indicators 
Measures of impact of living with visual 
impairment or an ophthalmic condition 
including quality of life (QoL), wellbeing, 
visual ability, functional vision, symptoms, 
functional status 
Parental reports of child’s behaviours (e.g. 
autism checklists, strength and difficulties 
questionnaire and other checklists of 
behaviours that are external to the child’s 
experience of impact of living with a visual/eye 
disability/disorder) 
 Clinician proxy measures (e.g., clinician’s 
questionnaire report on symptoms, QoL etc) 
 Visuo-spatial objective behavioural tasks for 
sighted children with specific cognitive delays 
(e.g. William’s Syndrome) 
Measures designed specifically for ophthalmic 
patients, eye-specific 
Generic measures only, not developed for 
vision/eyes  
Qualitative studies only if qualitative research 
was carried out as part of a PROM 
development  
Qualitative studies describing impact of 
eye/vision problem without an objective to 
develop a patient-reported outcome measure 
(PROM) 
 Review articles, letters, comments or articles 
without an abstract 
 Abstract not in English 
 
  
Table 2a: Instrument description – ‘All-Cause Generic Visual Impairment (VI)’ Instruments 
Instrument Year and 
Country 
Languages Eye Condition Age Range Respondent Input into 
items 
Number of 
Items  
Intended construct 
and/or domains  
Captured construct and/or domains  
Cardiff Visual 
Ability 
Questionnaire 
(CVAQC)55 
2010, UK English Visual 
Impairment 
5-18 years Child* Children 25 Visual Ability  Rasch-derived unidimensional scale 
capturing visual ability/functional 
vision 
Children’s Visual 
Function 
Questionnaire 
(CVFQ)46, 47 †  
2004, USA English Visual 
Impairment  
0-7 years Proxy Researchers 35 (age<3);   
40 (age 3-7)  
Vision-related 
Quality of Life  
 
Factor Analysis derived multi-
dimensional instrument with 
following subscales: 1) General 
Health, 2) General Vision, 3) 
Competence, 4) Personality, 5) 
Family Impact and 6) Treatment  
The impact of 
vision impairment 
on children 
(IVI_C)44, 45 
2011, 
Australia 
English Visual 
Impairment 
8-18 years Child*  Children, 
parents  
& teachers 
24  Vision-related 
Quality of Life  
Rasch-derived unidimensional scale 
capturing the impact of VI on 
participation in daily activities 
LV Prasad-
Functional Vision 
Questionnaire  
(LVP-FVQ)40 ‡ 
2003, India Indian 
English, 
Hindi, 
Telugu 
Visual 
Impairment 
8-18 years Child * Children, 
parents, 
clinicians & 
researchers 
20 § Functional 
Vision  
Rasch-derived unidimensional scale 
capturing visual ability/functional 
vision 
LV Prasad – 
Functional Vision 
Questionnaire 
Second Version 
(LVP-FVQ II) 39 ** 
2012, India Indian 
English, 
Hindi, 
Telugu 
Visual 
Impairment 
8-16 years Child * Children and 
parents  
 
23 Functional 
Vision  
Rasch-derived unidimensional scale 
capturing visual ability/functional 
vision 
Vision-related 
Quality of Life of 
Children & Young 
People 
(VQoL_CYP)35 
2011, UK English Visual 
Impairment 
10-15 
years 
Child  Children Under 
development 
Vision-related 
Quality of Life  
Instrument in development 
* Interviewer administered. 
† Used also outside of the original instrument development group85-88. 
‡  In a subsequent study by Nirmalan et al. 89, an 11-item version was applied and validated in a community sample. It is unclear how the shortened scale was derived, thus we only 
assessed for quality the original instrument. 
§ Summary score based on 19 items, with 1 item providing global rating of vision. 
** Second, stand-alone version of LVP-FVQ, see footnote (i). 
  
 Table 2b: Instrument description – ‘Eye-Disorder Specific’ Instruments 
Instrument Year and 
Country 
Language Eye Condition Age 
Range 
Respondent Input into 
items 
Number of 
Items  
Intended 
construct/domains  
Captured construct/domains  
Amblyopia Treatment 
Index (ATI)56-64 
2001, 
USA 
English Amblyopia 3-13 
years 
Child * & 
Proxy  
Parents, 
clinicians   
& 
researchers 
20 † (proxy 
version, age 
3-6) 
19 (child 
version, age 
7-13)  
Impact of 
amblyopia 
treatment 
Parent version: Factor Analysis derived 
multi-dimensional scale with following 
subscales relating to treatment of 
amblyopia: 1) Adverse effects, 2) 
Treatment compliance and 3) Social 
stigma. 
 
Child version: Factor Analysis derived 
multi-dimensional scale with following 
subscales relating to treatment of 
amblyopia: 1) Adverse effects, 2) 
Treatment compliance and 3) 
Functioning at near. 
Child Amblyopia 
Treatment 
Questionnaire (CAT-
QoL)38 
2011, 
UK 
English Amblyopia 5-7 
years 
Child Children In 
development 
Quality of Life Instrument in development 
Convergence 
Insufficiency Symptom 
Survey (CISS-V15)66-75 
‡ 
1999, 
USA 
English Convergence 
Insufficiency 
9-18 
years 
Child * Clinicians 
& 
researchers 
15 Symptoms Unidimensional scale capturing 
symptom severity (not derived 
psychometrically) 
Effects of Youngsters’ 
Eyesight on Quality of 
Life (EYE-Q)83, 84 
2010, 
USA 
English JIA-
Associated 
Uveitis 
8-18 
years 
Child Children 
& 
clinicians 
23 (age 8-
15);                  
26 (age 16-
18)       
Vision-related 
Quality of Life 
and/or Visual 
Function  
Unidimensional scale capturing visual 
ability/functional vision (not derived 
psychometrically) 
Emotional Impact of 
Amblyopia 
Questionnaire 
(EIAQ)65 
2004, 
UK 
English Amblyopia <67 
months 
Proxy Parents & 
clinicians 
15 Impact of 
amblyopia 
treatment 
Multi-dimensional scale capturing the 
impact of amblyopia treatment in form 
of following subscales (not derived 
psychometrically): 1) Child’s Experience, 
2) Family’s Experience, 3) Child’s Well-
Being 
Intermittent Exotropia 
Questionnaire 
(IXTQ)48-50 
2010, 
USA 
English Intermittent 
Exotropia 
5-17 
years 
Child § 
& Proxy  
Children 
& parents 
12 Health-Related 
Quality of Life 73  
Child version: Unidimensional scale 
capturing quality of life of children (not 
derived psychometrically) 
 
Parent version: Factor Analysis derived 
multi-dimensional scale with following 
subscales: 1) Function, 2) Psychosocial 
effects and 3) Surgery 
Nasolacrimal Duct 
Obstruction (NLDO) 
Questionnaire76-79 
2006, 
USA 
English Nasolacrimal 
Duct 
Obstruction 
6-48 
months 
Proxy Parents & 
clinicians 
29 ** 
  
Symptoms and 
Quality of Life 
A priory determined two-dimensional 
scale with following subscales: 1) 
Symptoms and 2) Child’s Health-Related 
Quality of Life  
Pediatric Refractive 
Error Profile 
(PREP)51-54 †† 
 
2006, 
USA 
English Refractive 
Error 
8-18 
years 
Child Not 
Reported 
26 Vision related 
functioning and 
wellbeing 
 
Multidimensional scale with following 
subscales (not derived psychometrically): 
1) Overall Vision, 2) Near Vision, 3) Far 
Vision, 4) Symptoms, 5) Appearance, 6) 
Satisfaction, 7) Activities, 8) Academics, 
9) Handling and 10) Peer perception 
Perceived Psychosocial 
Questionnaire (PPQ)81, 
82 
2002, 
UK 
English Amblyopia 3-5 
years 
Proxy Parents & 
clinicians 
10 Perceived 
Psychosocial 
Well-being of 
Child 
Item details not available 
Psychological Impact 
Questionnaire (PIQ)80 
2006, 
UK 
English Amblyopia, 
strabismus or 
refractive 
errors 
16-18 
years 
Child Children 
& 
researchers 
8 items 
(across 
4 scenarios) 
Psychological 
Impact 
Unidimensional scale capturing psycho-
social impact of strabismus (not derived 
psychometrically) 
Quality of Life in 
Children with Vernal 
Keratoconjunctivitis 
(QUICK)43 
2007, 
Italy 
Italian Allergic 
Conjunctivitis 
5-12 
years 
Child Children, 
parents,  
clinicians 
& 
researchers 
16 Quality of life Factor Analysis derived two-dimensional 
scale with following subscales: 1) 
Symptoms and 2) Daily Activities  
* Interviewer administered. 
† 18 questions, plus 2 items with a non-applicable option. 
‡ Used also outside of the original instrument development group90, 91. 
§ Interviewer administered for children 5-7 years.  
** 26 items, plus 3 non-scorable questions on the symptom scale. 
†† Used also outside of the original instrument group development92. 
  
Table 3a: Quality assessment and recommendations – ‘All-Cause Generic Visual Impairment (VI)’ Instruments 
Instrument Purpose Strengths Limitations Conclusions and recommendations 
CVAQC55 
 
Intended as a measure of 
self-perceived ability to 
perform vision-related 
tasks (i.e. visual ability) in 
children and young 
people with VI aged 5-18 
years. 
− Evidence of content and face validity, e.g. 
the instrument is grounded in the 
perspectives of visually impaired children 
and young people, collected through 
several focus groups. 
− Evidence of construct validity, internal 
consistency and statistically justified scoring 
using Rasch analysis.  
− Evidence of test-retest reliability 2-3 weeks 
later. 
− Focus groups that informed the instrument 
development included sighted children. As the 
measure is intended for visually impaired 
children, the role of sighted children is unclear 
and has not been justified. 
− Instrument not validated for use outside of the 
country of development (Wales, UK). 
Currently one of the most psychometrically 
robust measures of visual ability (i.e. 
functional vision) in children and young 
people with VI. It would serve as a valid 
and reliable PROM in evaluating the effect 
of low vision rehabilitation or other vision-
specific interventions for this population of 
children and young people, with 
appropriate cross-cultural adaptation and 
validation outside of the country of origin.  
CVFQ46, 
47 
 
Intended as a proxy 
measure of vision-related 
QoL for children with VI 
up to 7 years of age. The 
measure aims to capture 
difficulties in performing 
vision-related tasks, the 
effect of VI on the child’s 
personality and social 
behaviour, on the parents 
or family and on the 
attitude towards 
treatment.  
 
− One of the first measures developed to 
capture the impact of VI on children.  
− Evidence of construct validity: the scale 
discriminates between children with 
bilateral and unilateral cataracts, different 
levels of vision severity and treatment 
regimens.  
− Evidence of internal consistency across 
scales and age groups.  
− It has been translated into German and 
Portuguese88 (although only the German 
version was based on recommended cross-
cultural translation and validation 
approaches)86, 87. 
− Low content and questionable face validity: 
items were adapted from developmental tests 
and visual function instruments without any 
input from parents, children or external 
clinicians. Some items appear irrelevant to 
children younger than 3 years, regardless of 
their level of vision (e.g. ability to wash face or 
help with chores). Many items on the CVFQ 
address the parent’s own QoL, implying a 
separate ‘family impact construct’ that should 
be a separate subscale.  
− Test-retest reliability time averaged at 4.4 
months between the first and second 
instrument administration, which is longer 
than recommended.  
This is the only available measure for 
evaluating the impact of VI in younger 
children. Rather than a measure of the 
child’s QoL, it should be considered as a 
measure of parent-reported impact of 
childhood VI on the family and of the 
child’s vision-related competency. 
Consultations with parents and children 
where age-appropriate (e.g. 5-7) would 
enhance the content validity of the scale. 
Further, appropriate cross-cultural 
adaptation and validation outside of the 
country of origin (USA) should also be 
taken into account if considered for use by 
researchers and clinicians. 
IVI_C44, 45 
 
Intended as a vision-
specific QoL instrument 
for visually impaired 
children and young 
people aged 8-18 years.  
− The first paediatric measure of the impact 
of VI on children using Rasch analysis 
measurement model to provide a precise, 
statistically justified scale.  
− Evidence of content and face validity e.g. 
through focus groups with children and 
young people, as well as professionals.   
− Evidence of construct validity, internal 
consistency and statistically justified scoring 
using Rasch analysis.  
 
− The young people’s views (particularly those of 
children aged 8-11 years) during item 
generation may have been under-represented 
compared to those of the adult stake holders’ 
(e.g.  19% vs. 81% in focus groups 
respectively), contrasting with the established 
idea of QoL being a subjective construct. 
− Questionable choice of assessment (Guttman 
split-half) of test-retest and of mode and inter-
observer reliability. 
− It has not been validated for use outside of the 
Currently one of the most psychometrically 
robust vision-related PROMs available. 
The scale captures the broader impact of 
living with VI, with a specific focus on 
daily activities. It can be a useful tool in 
evaluating the effectiveness of low vision 
rehabilitation or treatment intervention in a 
wider population of children and young 
people with VI aged 8-18 years, with 
appropriate cross-cultural adaptation and 
validation outside of the country of origin. 
country of development (Australia).  
LVP-
FVQ40 
 
Intended as a measure of 
functional vision in 
visually impaired school-
aged children in India.  
 
− Evidence of content and face validity i.e. 
through focus groups and interviews with 
clinicians, children and parents as well as a 
literature review informing the instrument’s 
items. 
− Evidence of convergent validity through 
Rasch analysis  
− It has been translated into Arabic for use 
with Egyptian children (although 
recommended cross-cultural translation 
and validation approaches were not 
reported 93). 
− Low reliability evidenced through Rasch 
analysis e.g. disordered response categories and 
inadequate outfit statistics and standardised 
residuals, as well as low person reliability and 
person separation statistics. 
− No evidence of test-retest reliability. 
 
Despite good content validity, it has limited 
psychometric properties and the second 
version LVP-FVQ II is recommended 
instead. 
LVP-
FVQ II 39 
Intended as a measure of 
functional vision in 
visually impaired school-
aged children aged 8-16 
years in India.  Intended 
as a distinct, 
psychometrically superior 
version of the original 
LVP- FVQ. 
 
− Evidence of content and face validity e.g. 
through focus groups and interviews with 
children and parents as well as a literature 
review of existing questionnaires and 
adapting items from other similar, validated 
measures for this population. 
− Evidence of construct validity, internal 
consistency and statistically justified scoring 
using Rasch analysis  
− Evidence of test-retest reliability 2 months 
later. 
− Cross-culturally validated for 3 main 
languages spoken in India 
− Although ‘not applicable’ response category 
was included in instrument, its utilisation by 
responders, nor the presentation of missing 
responses, has not been reported. 
− It has not been validated for use outside of the 
country of development (India). 
 
 
This 2nd version of the LVP-FVQ is 
psychometrically superior and is 
recommended for use instead of the 
original LVP-FVQ. The instrument would 
serve as a valid and reliable PROM in 
evaluating the effect of low vision 
rehabilitation or other vision-specific 
interventions for children and young 
people with VI aged 8-16 years, with 
appropriate cross-cultural adaptation and 
validation outside of the country of origin. 
Table 3b: Quality assessment and recommendations – ‘Eye-Disorder Specific’ Instruments 
Instrume
nt 
Purpose Strengths Limitations Conclusions and recommendations 
ATI 56-
64 
Intended to measure 
the impact of amblyopia 
treatment as part of 
study trials of the 
acceptability of 
treatment and its impact 
on the child and family. 
Initially intended as a 
proxy measure for 
children aged 3-7 
years56 (we refer to this 
as ATI-proxy), it has 
more recently been 
adapted for children up 
to 13 years59 (we refer 
to this as ATI-child).   
− Evidence of construct validity: a) ATI-proxy 
discriminates between children receiving 
different treatment regimens such as patching, 
atropine drops and Bangerter filters, suggesting 
it can be a useful scale for evaluating the 
parent-perceived effect of treatment 
interventions; b) ATI-child discriminates 
between children receiving patching and those 
receiving atropine drops. 
− ATI-proxy captures three Factor Analysis 
determined domains, which showed good 
internal consistency (excluding misfitting 
items).57, 58 
− It has been translated into Korean (although 
recommended cross-cultural translation and 
validation approaches were not reported)94. 
− Questionable internal consistency: poor fitting 
items identified through psychometric validation 
remain in the scale in subsequent publications.   
− Questionable content validity: a) the process of 
ATI-proxy item generation has largely been led 
by literature review and professional opinion with 
minimal input from parents or patients; b) ATI-
child was designed ad hoc from ATI-proxy 
without the input of children. 
− No evidence of test-retest reliability. 
 
If using ATI-proxy, excluding the 
misfitting items (e.g. 15 and 17) is 
recommended. ATI-child is not 
recommended in its current form as its 
development is not grounded in children’s 
own views, being an adapted version of a 
parental form. Further construct validity 
testing against another measure and 
further development, including 
consultations with patients with regards to 
including new and/or revising existing 
items, are needed to enhance the currently 
limited psychometric properties of the 
proxy version and to create a valid and 
reliable child self-report version of this 
instrument. Cross-cultural adaptation and 
validation is also required for use in 
countries not included in the Pediatric Eye 
Disease Investigator Group’s (PEDIG) 
randomised control trials sites. 
CISS-
V15 66-
75 
 
Developed by the 
Convergence 
Insufficiency and 
Reading Study group 
specifically for a survey 
of symptomatic school 
aged children suffering 
from convergence 
insufficiency (CI). Both 
child and proxy 
versions of the scale are 
available.  
 
− The only patient-reported measure available for 
children with CI.  
− Evidence of face validity. 
− Evidence of test-retest reliability 2 weeks later. 
− Evidence of construct validity: the scale 
discriminates between children with CI and 
those with normal vision.  
− The authors have calculated the cut-off point 
for symptomatic children and also the minimal 
difference needed for a clinically significant 
change, making the tool useful for monitoring 
therapeutic interventions (although authors 
caution against using it as a screening tool, as it 
would not pick up a child who is asymptomatic 
due to avoidance of symptom-related tasks). 
− High internal consistency (α >.90, although 
− Questionable content validity: Symptomatic 
children and their parents were not included in 
instrument development.   
− No formal psychometric item reduction or 
standard construct validation approaches (e.g. 
testing against a clinical symptom assessment) 
have been applied.  
Potentially useful for monitoring 
therapeutic interventions, although it 
cannot be used for screening purposes.  
This instrument should be used with some 
caution as the scale has not been derived 
through standard psychometric item 
reduction approaches, hence the summary 
score is not fully statistically justified.  
Appropriate cross cultural adaptations 
should also be considered for use outside 
of the country of origin (USA). 
 
such high Cronbach alpha may be indicative of 
some item redundancy37). 
− Used in Australia95, 96 and translated into 
Hebrew 90, although no cross-cultural 
adaptation methods reported. 
EYE-Q 
83, 84 
 
Intended as a measure 
of vision-related quality 
of life (VQoL) and 
visual function in 
juvenile idiopathic 
arthritis (JIA) patients 
with related uveitis, 
aged 8-18 years. 
− The only available JIA-specific child-
appropriate measure.  
− Evidence of content validity: items were 
derived from interviews with paediatric 
rheumatologists, optometrists and children with 
and without VI.  
− Evidence of test-retest reliability 10 days later.  
− Evidence of construct (known groups) validity: 
the scale discriminates between groups on the 
basis of the level of vision impairment. 
− High internal consistency (α>.90, although such 
Cronbach alpha may be indicative of some item 
redundancy). 
− Questionable face validity: The measure lacks 
clarity regarding its purpose and underlying 
construct, being interchangeably referred to as a 
measure of visual function83 and VQoL, despite 
the authors’ acknowledgement that the two are 
distinct constructs84. Based on the actual content 
area, the questionnaire is likely a measure of 
functional vision. This is further evidenced by 
EYE-Q scores being weakly associated with 
HRQoL (measured using  generic measure 
PedsQL97), but moderately correlated with visual 
acuity and contrast sensitivity.  
− The final scale and summary scoring has not been 
informed by the standard psychometric item 
reduction approaches. 
− No cross-cultural validation undertaken outside 
of the country of development (USA).  
The EYE-Q shows promise as a measure 
of functional vision, rather than of VQoL 
in children with JIA. It is currently 
undergoing further developments and it is 
recommended that any revisions of the 
scale are taken into account before 
considering using this scale. Cross-cultural 
adaptation and validation are also needed 
before it can be used outside of the 
country of origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3c: Quality assessment and recommendations – ‘Eye-Disorder Specific’ Instruments (continued) 
Instrume
nt 
Purpose Strengths Limitations Conclusions and recommendations 
IXTQ 
48-50  
 
Intended as a measure 
of QoL in children with 
IXT, IXTQ comprises 3 
versions, 2 of which 
concern the child’s QoL 
(child and proxy 
versions) and one 
addressing the parental 
QoL (the latter 
excluded from quality 
assessment in this 
review). 
− Evidence of content validity: the scale is 
grounded in the experience of exotropic 
children and addresses the psychosocial and 
subjective experience of the child.  
− Evidence of construct (known groups) validity: 
the scale discriminates between children with 
IXT and controls (orthotropic children with a 
median visual acuity of 20/20). 
− There are complementary proxy and age-
appropriate self-report versions, including a 
self-report version for children aged 5-7, which 
in the literature is often substituted by proxy 
report.  
− High internal consistency (α >.90, although 
such high Cronbach alpha may indicate some 
item redundancy). 
− Questionable statistical justification provided for 
deriving the summary IXTQ score, e.g. 
subnormal cut-off and ‘normative’ scores for 
QoL calculated and based on a small sample.  
− No evidence of test-retest reliability. 
− It has not been translated and validated for use 
outside of the country of development (USA) 
The IXTQ has good content grounding, 
having been developed from the concerns 
raised by children with IXQT and shows 
promise as a condition-specific PROM for 
this population. Both parent and child 
versions were developed in parallel and are 
complementary for capturing their distinct 
perspectives. Further psychometric testing 
(including comparison of children with 
IXT receiving different treatments for the 
condition, test-retest reliability testing and 
further item reduction) should be 
considered for this scale as well as 
appropriate cross-cultural adaptation and 
validation if used outside of the country of 
origin. 
 
NLDO 
76-79 
 
Developed as part of 
research trials by 
PEDIG, NLDO was 
intended as a proxy 
measure of symptoms 
and health-related QoL 
(HRQoL) in children 
with the condition aged 
6 to 48 months. 
− The only PROM available for this population.  
− Evidence of content validity: content is based 
on interviews with parents of children with 
NLDO, and discussions with clinicians.  
− Evidence of construct (known groups) validity: 
the scale discriminates between children with 
and without the condition 
− Evidence of responsiveness: the scale shows 
sensitivity to changes in the condition due to 
treatment intervention77-79. 
− High internal consistency for both the 
questionnaire as a whole and the symptoms 
scale, although not the HRQoL scale (α >.90, 
although such high Chronbach alpha may be 
indicative of some item redundancy). 
− The summary scoring is based on items on an a 
priori decided subscale (Symptoms and HRQoL) 
that did not withstand psychometric item 
reduction. 
− Questionable face validity: The HRQoL subscale 
items combine the impact of NLDO on both 
parent and the child, implying the underlying 
construct measured is ‘the impact on the family’ 
rather than  the subjective HRQOL of  the child 
(with only two questions relating specifically to 
the child’s experience). 
− No evidence of test-retest reliability. 
− It has not been validated for use outside of the 
country of origin (USA). 
Although potentially useful as a measure 
of symptoms and family impact of the 
child’s condition when monitoring the 
progression of NLDO treatment in 
affected children, NLDO is not 
recommended as a measure of child’s 
HRQoL. Further psychometric validation 
with larger samples should be considered 
for this scale as well as cross-cultural 
adaptation and validation for use outside 
of the country of origin. 
 
 
PIQ 80 
 
Intended for assessing 
the psychological 
impact in general daily 
life of amblyopia, 
strabismus and 
refractive error in 
teenagers aged 16-18 
years. 
− Evidence of content validity: item development 
grounded in the views of amblyopic 
adolescents.   
− Evidence of test-retest reliability 2-4 weeks 
later.  
− Evidence of construct validity: low correlations 
with an adult visual function questionnaire (VF-
1412) and significantly different PIQ scores 
between cases and controls with normal vision. 
− The scale has not been subjected to formal 
psychometric item reduction and the summary 
score has not been statistically justified. 
− Despite enlisting the help of adolescents when 
developing the instrument it is unclear how items 
were generated and evaluated for relevance and 
to what extent adolescents were involved.  
− It has not been validated for use outside of the 
country of development (UK). 
PIQ could be useful as a starting point for 
potential items tapping the psychosocial 
impact of amblyopia, strabismus or 
refractive error on young people. 
However, its use as a valid and reliable 
PROM is limited, as the suitability of the 
items has not been formally tested through 
appropriate psychometric approaches, nor 
has the scale been cross-culturally 
validated for use outside of the country of 
origin. 
QUICK 
43 
 
Developed in Italy to 
measure the impact of 
ocular allergy on 
HRQoL in children 
aged 5-12 years. 
− Currently the only instrument available 
specifically for this population.  
− Evidence of content validity: both user (parents 
and children) and professional views (literature 
review as well as clinicians’ opinion) were 
considered when developing instrument items.  
− The two-dimensional QUICK scale (Symptoms 
and Daily Activities) possesses adequate 
internal consistency and construct validity, with 
both subscales correlating highly with the 
disease subscale of the KINDL98 (a generic 
HRQoL instrument) and the Symptoms 
subscale correlating with clinical symptom 
parameters. 
− The item reduction approach using Factor 
Analysis (requiring large samples) was based on 
very small samples, limiting reliability.  
− Questionable face validity: prior to Factor 
Analysis, the authors removed the ten lowest 
scoring items with little statistical justification, 
eliminating most of the items tapping 
psychosocial aspects of QoL. Contrary to its title, 
the QUICK appears to be largely a symptom 
scale, with only four items tapping participation 
in daily activities.  This is further evidenced by 
the significant correlation with the disease 
subscale of the KINDL98 and the absence of an 
association with important psychosocial 
indicators of HRQoL such as well-being and self-
esteem. 
− No evidence of test-retest reliability. 
− English translation of the instrument has been 
undertaken by the authors without recommended 
cross-cultural translation and validation 
approaches. 
Although the only paediatric PROM 
available specifically for this population, 
psychometric approaches to developing 
QUICK were significantly limited, 
suggesting it should be used with caution. 
QUICK can be used as a symptom scale, 
rather than a measure of QoL, but the 
broader impact of living with vernal 
keratoconjunctivitis needs to be 
incorporated into the scale, as well as 
appropriate psychometric validation with a 
larger group of participants.  Appropriate 
cross-cultural adaptation and validation is 
recommended before use outside of the 
country of origin. 
 
 
 
 
